Mehrad M, et al. - The prognostic clinicopathological and genetic characteristics of pulmonary sarcomatoid carcinomas (PSCs) was evaluated in this analysis. For this investigation, 53 cases of surgically treated PSCs were chosen, 23 of which were subjected to mutation and copy number variation analysis using the 50-gene Ion AmpliSeq Cancer Panel. Although most of these tumors harbor currently prognostically adverse TP53 and KRAS mutations which are hard to target, potentially targetable mutations could be identified in a subset of PSC.